The short version
This page uses the fragment identity discussed in FDA’s July 2026 TB-500 briefing. Match the actual substance before comparing studies.
An investigational profile is not an endorsement or a finding of safety.
What does TB-500 mean?
TB-500 is a common name used inconsistently in commercial descriptions. FDA’s July 2026 briefing examines an acetylated seven-amino-acid fragment, LKKTETQ. Full-length thymosin beta-4 contains 43 amino acids. These are different molecules; findings for one do not automatically apply to the other.
Check the sequence, terminal modifications and salt form in a source before comparing its findings. Consistent use of the name TB-500 does not establish that different preparations contain the same substance.
An example of why identification matters
A commercial KLOW listing checked on 8 November 2026 calls its ingredient a fragment but gives a molecular weight of 4963.44 g/mol. FDA’s short-fragment description gives 889.01 g/mol. That is a description inconsistency, not a finding about actual vial contents.
FDA briefing: fragment identity and naming limitations ↗ · Commercial description used for the example ↗
The commercial reference documents wording only. It is not an endorsement or a supplier assessment.
Names you may see
Compound names, research identifiers, brand names and informal shorthand serve different purposes.
- TB-500 / TB500
- Name and spelling variant · A label used inconsistently across sources.
- Thymosin beta-4
- Related name—check identity · Full-length thymosin beta-4 must not automatically be equated with a fragment labeled TB-500.
- Thymosin beta-4 fragment / LKKTETQ
- Fragment terminology—check identity · A fragment sequence is not the same molecule as full-length thymosin beta-4. Check exactly which sequence a source describes.
Similar names do not establish identical ingredients, molecular variants, product quality or interchangeable preparations. A blend nickname may describe different formulas.
Things worth checking
Is the paper about the fragment or the full-length peptide?
Check whether a source evaluated the short fragment or full-length thymosin beta-4, and whether its preparation matches the claim.
Substance-identification context · FDA · July 2026 TB-500 briefing ↗
Questions to bring to a clinician or pharmacist
- Which findings apply to my goal and medical history?
- Could my medicines, supplements, or other compounds change the assessment?
- What monitoring, if any, would inform a decision—and what symptoms would need evaluation?
Monitoring is individual. Normal bloodwork does not establish that a compound or preparation is safe.
Clinical research
The July 2026 FDA briefing reports that its review did not identify human clinical studies of the evaluated TB-500 forms. That is the agency’s dated review, not a claim about every study ever conducted.
Research terms in everyday language ↗
Selected FDA assessment and its naming distinctions reviewed. A committee briefing is not a final legal determination; current legal status and comprehensive clinical appraisal are not assessed here.
Read findings in the context of the exact product or preparation, the people studied, and the outcome measured. These draft profiles are starting points, rather than complete systematic reviews.
Community research
Structured community reports can help identify questions worth studying. They are considered separately from controlled studies, with their limitations kept visible.
No community reports published yet.
This profile has no published community dataset. We do not infer a trend or a benefit from missing reports.
How community research will work ↗What we will document about community advice
- The advice
- What people recommend, with dated sources and the scope of the discussions examined.
- The reasoning
- Why contributors believe it helps, without treating that explanation as an established mechanism.
- The evidence
- What supports the claim, contradicts it, or has not been tested.
- The cautions
- Possible downsides, conflicting experiences, and questions for a clinician or pharmacist.
No recommendation or community consensus is established by this framework. Descriptions of how common advice is will need documented source coverage.
A closer look
- Classification
- Thymosin beta-4 fragment context
- Name variations
- Names you may see and important distinctions
- Source type
- FDA advisory-committee briefing · historical assessment
- Reference jurisdiction
- United States
Interpret the source in the context of the preparation and route it discusses. A regulatory notice and a controlled clinical trial answer different questions.
This first design edition reserves space for study-by-study summaries, definitions, and technical references as each profile receives editorial review.
Go to the source
Study cards identify whether the summary uses an abstract, full text, or an agency assessment. Follow the linked sources for their original context.
Source reference · Checked 8 November 2026 · Opens in a new tab
Page 38 is a nominator-authored submission, distinct from FDA’s own assessment.
For athletes: competition rules are a separate check ↗